Press Releases

November 12, 2019
CASI Pharmaceuticals Announces Third Quarter 2019 Financial Results
November 07, 2019
CASI Pharmaceuticals Enters Exclusive China Distribution License Agreement For Octreotide Long Acting Injectable (LAI) Microsphere For Neuroendocrine Cancers And Acromegaly
September 05, 2019
CASI Pharmaceuticals, Inc. to Host Key Opinion Leader Symposium on September 10, 2019 in New York City
September 03, 2019
CASI Pharmaceuticals, Inc. To Present At The 2019 H.C. Wainwright 21st Annual Global Investment Conference
August 12, 2019
CASI Pharmaceuticals Announces Launch of EVOMELA® (melphalan for injection) in China
August 09, 2019
CASI Pharmaceuticals Announces Second Quarter and First Half 2019 Financial and Business Results
June 17, 2019
CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
June 03, 2019
CASI Pharmaceuticals To Present At The 2019 BIO International Convention
May 15, 2019
CASI Pharmaceuticals Announces First Quarter 2019 Financial and Business Results
April 17, 2019
CASI Pharmaceuticals In-Licenses Exclusive Worldwide Rights to Novel Anti-CD38 Monoclonal Antibody Program From Black Belt Therapeutics
April 02, 2019
CASI Pharmaceuticals Announces The Appointment Of Wei-Wu He, Ph.D., Executive Chairman, To The Role Of Chief Executive Officer
March 29, 2019
CASI Pharmaceuticals Announces Fourth Quarter And Full Year 2018 Financial Results And Business Results
March 13, 2019
CASI Pharmaceuticals Announces Exclusive Distribution Partner For Melphalan Hydrochloride For Injection (EVOMELA®) In China
March 07, 2019
CASI Pharmaceuticals Announces China National Medical Products Administration (NMPA) Approval Of CTA To Conduct Registration Trial For MARQIBO®
February 19, 2019
CASI Pharmaceuticals Announces China National Medical Products Administration (NMPA) Approval Of CTA To Conduct Confirmatory Clinical Trial For ZEVALIN®
February 06, 2019
CASI Pharmaceuticals to Present at the BIO CEO & Investor Conference
December 03, 2018
CASI Pharmaceuticals Announces China Market Approval Of Melphalan Hydrochloride For Injection (EVOMELA^®)
November 16, 2018
CASI Pharmaceuticals To Build GMP Manufacturing Site In Wuxi, China
November 14, 2018
CASI Pharmaceuticals Announces Third Quarter and First Nine Months 2018 Financial and Business Results
October 23, 2018
CASI Pharmaceuticals Acquires HBV ANDA from Laurus Labs Limited

Page 3 of 14 pages < 1 2 3 4 5 > Last ›

INVESTOR CONTACT:

Jennifer Porcelli
Solebury Trout
740 Broadway
New York, NY 10003

Ph: 646.378.2962
Email: jporcelli@troutgroup.com

About Us

CASI is a U.S. NASDAQ-listed biopharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, the U.S., and throughout the world. We have offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China, through which substantially all of our operations are conducted.

Downloads

Corporate Presentation

EVOMELA^® (melphalan) for Injection, ZEVALIN^® (ibritumomab tiuxetan), and MARQIBO^® (vincristine sulfate LIPOSOME injection) are proprietary to Acrotech Biopharma LLC and its affiliates.

CASI Pharmaceuticals

© 2020 CASI Pharmaceuticals Inc.
All Rights Reserved.